Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Rare disease research: grey literature is the new knowledge currency

Posted on March 27th, 2020 by in Pharma R&D

Pharma research for rare disease is challenging because of insufficient patient populations available for clinical trials, and also because the investment returns are marginal. Thus, grey literature is an important source of information for rare disease research—and, fortunately, grey literature data is increasingly being recognized as highly valuable to the scientific community.

(more…)

Working together to get the best out of AI for all

Posted on April 16th, 2019 by in Pharma R&D

Go to any conference these days and the number one buzzword is AI. However, despite all the excitement, AI is still talked about in fairly vague terms – with few people able to pin down exactly what they mean by AI. New research from some of my Elsevier colleagues examined this phenomenon.

(more…)

Three ways to reduce the cost of precision medicine

Posted on March 12th, 2019 by in Pharma R&D

In December 2018, the FDA announced it has formally recognized a public database containing genomic information, a huge milestone in the evolving field of precision medicine. Now researchers can use this information to validate their tests instead of having to generate their own data.

(more…)

Quantitative Proteomics: A Major Piece in the Precision Medicine Puzzle

Posted on December 22nd, 2017 by in Pharma R&D

Our genetic make-up, where we live and how we live, are all important factors to consider when we are dealing with disease. For a very long time, medicine has mostly been designed to treat the sickness without much thought to the individual who has it. (more…)

  1. 1
  2. 2
  3. 3
  4. 5